Can AI Find the Right Cancer Drug for the Right Patient? This Collaboration Is Putting It to Work

Important Disclosures:

1. Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc. 
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Key Investor Takeaways

• Rakovina Therapeutics launched a new AI-driven cancer drug development collaboration with Celvion Therapeutics, using Celvion's EMphora artificial intelligence platform to analyze real-world clinical outcomes and patient data for Rakovina's ATR inhibitor program.
• The AI collaboration will search for drug combinations, predictive biomarkers, and patient populations for ATR-targeted cancer therapies, with the companies expecting the work to generate clinically actionable hypotheses for future combination studies and biomarker-driven patient selection.
•  Rakovina's kt-5000AI ATR inhibitor program has multiple development milestones as outlined in the May 2026 investor presentation, including lead optimization, lead selection, and ongoing partner discussions. The company's development timeline listed an ATR lead selection for Q4 2026 and GLP toxicology and IND-enabling studies for H1 2027.
• Rakovina is advancing three AI-powered DNA damage response cancer drug programs, including the kt-5000AI ATR inhibitor, the kt-3000 dual PARP/HDAC program, and the kt-2000AI PARP inhibitor program.
• Additional 2026 and 2027 cancer drug development catalysts span all three programs, including continued in vivo studies for the PARP/HDAC program, advancing PARP lead candidate selection, GLP toxicology and IND-enabling studies, and development of strategic pharmaceutical partnerships.

Rakovina Therapeutics Partners With Celvion on AI-Driven ATR Cancer Drug Development

Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) announced a research collaboration with Boston-based Celvion Therapeutics to use Celvion's proprietary EMphora artificial intelligence platform to identify precision medicine strategies for Rakovina's ATR inhibitor program.

The collaboration will use artificial intelligence to examine large-scale clinical outcomes and real-world patient data to identify therapeutic targets that may enhance the activity of Rakovina's ATR inhibitor. The analysis will evaluate potential drug combinations while searching for previously unrecognized therapeutic opportunities, predictive biomarkers, and patient subgroups most likely to benefit from ATR-targeted therapies.

Rakovina and Celvion aim to use the work to improve development efficiency, reduce clinical risk, and accelerate precision cancer drug development.

The companies expect the analysis to generate clinically actionable hypotheses that could be used to prioritize future combination studies, guide biomarker-driven patient selection strategies, and inform the design of subsequent clinical development programs.

"We have learned how to use multiple specialized AI platforms to accelerate the drug discovery and development process rather than relying on a single platform. Our team selects the right tool for each challenge, from generative design to large-scale screening, to develop molecules that exploit vulnerabilities in how cancer cells repair DNA damage," Rakovina Chief Executive Officer Kim Oishi said. "Working with Celvion extends that approach into clinical strategy, using advanced AI to identify the patient populations and drug combinations where our ATR inhibitor program can have the greatest impact."

Celvion Chief Executive Officer Mi Yang said EMphora was developed to derive therapeutic insights from clinical outcomes and existing patient data.

"By collaborating with Rakovina, we have an opportunity to identify combination therapies and biomarkers that may not be apparent through conventional research methods," Yang said. "Our objective is to generate actionable evidence that helps guide smarter clinical development and ultimately benefits patients."

Rakovina President and Chief Scientific Officer Dr. Mads Daugaard said the collaboration would allow the company to evaluate ATR-based combination strategies while examining additional biomarkers and therapeutic targets.

"Synthetic lethality offers tremendous promise in oncology, but its greatest impact will come from identifying the right combinations for the right patients," Daugaard said. "This collaboration gives us the opportunity to rigorously evaluate ATR-based combination strategies while exploring additional biomarkers and therapeutic targets that could further enhance clinical benefit. These insights will help shape the next generation of our development strategy."

Rakovina and Celvion intend to commit scientific, technical, and other resources to the collaboration. As the work progresses and development opportunities are identified, the companies expect to explore potential co-development and economic arrangements for subsequent stages of development.

Rakovina described the collaboration as part of its broader strategy of combining computational biology, translational science, and precision oncology in cancer drug development. The company is focused on developing cancer treatments targeting the DNA-damage response and has established a pipeline of DNA-damage response inhibitors, with the goal of advancing one or more candidates into human clinical trials in collaboration with pharmaceutical partners.

AI Drug Discovery and Oncology Sector

A September 4 report from Google Australia described cancer drug development as a slow and inefficient process, stating that approximately 95% of oncology drugs entering human clinical trials failed to reach approval. The report examined the use of artificial intelligence, cloud computing, machine learning, and three-dimensional human tissue models to improve drug development. It said machine learning could connect molecular tumor maps with laboratory-tested drug responses and clinical outcomes, with the goal of predicting drug efficacy from a tumor's molecular profile. The report identified clinical trial design as an immediate application, stating that predicting which patient groups were most likely to benefit could support smaller, more targeted trials. It said the approach could help prevent viable drugs from being abandoned because they were "trialed on the wrong patient populations."

Technology had become the "biggest structural shift in oncology drug development over the past 5 years," according to David Spigel, MD, president and chief medical officer of Sarah Cannon Research Institute, in a September 30 interview with The American Journal of Managed Care. Spigel discussed AI's potential role as the number of therapies and clinical trials increased. "It's not hard to imagine with the breadth of drugs in development, the number of clinical trials that are increasing, technology is going to be one of the key drivers of helping us sort through that clutter, that traffic jam of competing drugs, competing trials, and patients to get matched to those therapies," he said.

Spigel said the oncology field remained early in determining how AI could be applied across drug development, clinical trial design, patient recruitment, assessment of results, and endpoint discovery. He also discussed increasingly complex trial designs built around biomarker-defined patient subsets and adaptive protocols. Improved molecular testing has allowed clinicians to track treatment response through measures including minimal residual disease in the blood. "We'll probably even get to a place where we understand areas where maybe you don't think you need a target or expression of a marker to predict benefit from a therapy," Spigel said.

The increasing role of patient selection, molecular subtyping, and AI in oncology development was also discussed during a September 28 OncoDaily and ZS webinar on the state of oncology. Matt Furlow, PhD, said aggregate cancer outcomes could conceal unmet needs within particular subtypes, resistant disease, and later treatment lines. The discussion examined more precise molecular subtyping as a way of identifying opportunities within established disease categories.

The webinar also addressed patient-centered approaches to drug discovery. One biotechnology executive participating in the discussion said, "So our whole premise is that clinical trial failure rates are high in part because the wrong patient population is targeted and, thus, the wrong biology is targeted." The approach described during the webinar involved evaluating drug candidates against biological patterns, including genomic patterns associated with better or worse patient outcomes.

Competition around established biological targets had also increased. According to the analysis presented by Furlow, the average number of assets per individual target had doubled between 2010 and 2024. "But commercially, this signals crowding and diminishing differentiation," he said. The discussion described evaluating both therapeutic targets and treatment modalities as one method of identifying less crowded areas for development.

Patient needs remained another focus of oncology portfolio development. "What is the unmet need and what are you hoping to address with what you're bringing to the table?" one biotechnology executive said during the September 30 discussion. The webinar also examined partnerships and platform validation, including a shift among the leading oncology companies analyzed toward earlier-stage deals and platform licensing. For early-stage technology platforms, the discussion identified the need to validate both individual drug candidates and the technologies used to discover them, while also describing a funding gap between promising preclinical research and the clinical evidence sought by investors.

Drug Development Milestones Extend Through 2027

Rakovina's Q2 2026 investor presentation outlined ongoing and upcoming work across three drug development programs, including its ATR program, dual PARP/HDAC program, and PARP program.

The company's kt-5000AI program is developing an ATR inhibitor designed for central nervous system penetration. The program uses generative AI and targets solid tumors, PTEN-deficient cancers, and CNS metastases. According to the presentation, 138 molecules had been predicted, 43 had been synthesized, and leads had been confirmed as potent and selective. CNS penetration and tolerability had also been confirmed in vivo. The company listed 2026 milestones, including in vivo model data at peer-reviewed meetings, lead-optimization results from an expanded AI collaboration, lead selection, and ongoing partner discussions.

Additional data included in the investor presentation showed that candidate ATR inhibitors had varying levels of CNS penetrance, activity, and metabolic stability that the company said were broadly consistent with AI predictions. Compound D showed equal in vivo efficacy compared with ceralasertib, with decreased weight loss and no signs of hematological toxicity. Further optimization of candidate inhibitors was ongoing.

For its kt-3000 program, Rakovina is developing a dual PARP/HDAC inhibitor for PARP-resistant adult and childhood cancers, including Ewing sarcoma. The presentation said kt-3283 demonstrated superior cytotoxicity compared with FDA-approved olaparib and vorinostat, and the program had been published in Clinical Cancer Research and presented at the AACR Annual Meeting in April 2026.

The program also includes a joint venture with NanoPalm that combines Rakovina's AI drug discovery with NanoPalm's self-targeting patterned lipid nanoparticle delivery system. Rakovina said it retains intellectual property rights and described the funding as non-dilutive. Listed 2026 milestones included securing joint venture funding, an ADC partnership, and nano-lipid formulation data at peer-reviewed meetings.

Development work on pLNP-kt-3283 was also continuing. The presentation said the compound could be encapsulated into a patterned lipid nanoparticle designed by the EnsaliX AI platform. Further development included in vitro and in vivo characterization to confirm activity against PARP and HDAC enzymes, determine ADME properties, and assess efficacy against in vivo tumor models.

Rakovina's third program, kt-2000AI, is a brain-penetrant PARP inhibitor using the deep docking platform and targeting breast, ovarian, and prostate cancers. The company said billions of compounds had been screened through Deep Docking, with 389 compounds assessed against PARP. Leads had been confirmed with PARP selectivity and drug-like properties.

The company's broader development timeline detailed work extending into the first half of 2027. In the third quarter of 2026, Rakovina planned in vivo ADME and efficacy work and advanced lead candidate selection for the ATR program, continued in vivo studies for the PARP/HDAC program, and finalized a Saudi joint venture at the corporate level.

For the fourth quarter of 2026, Rakovina listed the selection of an ATR lead, another round of AI output, and advancing lead candidate selection for the PARP program, institutional funding, and participation in the SNO, AACR-NCI-EORTC, and BIO Middle East conferences.

In the first half of 2027, the company's timeline called for GLP toxicology and IND-enabling studies for both the ATR and PARP/HDAC programs, lead selection for the PARP program, and continued development of strategic pharmaceutical partnerships.

Ownership and Share Structure¹

Edison Oncology holds approximately 9.9% of Rakovina Therapeutics. Management and reporting insiders account for about 9.64% ownership, with the remainder held by a combination of institutional, retail, and other investors, as previously disclosed in company materials.

As of September 2, 2026, Rakovina Therapeutics had approximately 44.32 million issued and outstanding shares, and the company's market capitalization was approximately CA$10.2 million. Rakovina's shares had traded within a 52-week range of approximately CA$0.09 to CA$0.47 per share.

Frequently Asked Questions About Rakovina Therapeutics, AI Drug Discovery, and Cancer Drug Development

What is Rakovina Therapeutics' new AI cancer drug development collaboration?
Rakovina Therapeutics announced a research collaboration with Celvion Therapeutics to use Celvion's EMphora artificial intelligence platform to analyze large-scale clinical outcomes and real-world patient data for Rakovina's ATR inhibitor program. The work will examine potential drug combinations, therapeutic targets, predictive biomarkers, and patient populations.

How is Rakovina Therapeutics using artificial intelligence for cancer drug discovery?
Rakovina uses specialized AI platforms across its drug discovery and development work. Its pipeline includes the kt-5000AI ATR inhibitor program, the kt-3000 dual PARP/HDAC program, and the kt-2000AI PARP inhibitor program.

What is Rakovina Therapeutics' ATR inhibitor program?
Rakovina's kt-5000AI program is developing an ATR inhibitor designed for CNS penetration. The program targets solid tumors, PTEN-deficient cancers, and CNS metastases and uses generative AI in its drug discovery and lead-optimization work.

What are predictive biomarkers in AI-powered oncology drug development?
In the Rakovina and Celvion collaboration, the EMphora platform will analyze clinical outcomes and real-world patient data to search for predictive biomarkers and patient subgroups most likely to benefit from ATR-targeted therapies.

What are Rakovina Therapeutics' upcoming drug development catalysts?
The company's development timeline listed ATR lead selection and further PARP AI work for Q4 2026. For H1 2027, Rakovina listed GLP toxicology and IND-enabling studies for its ATR and PARP/HDAC programs, PARP program lead selection, and continued development of strategic pharmaceutical partnerships.

What is the role of AI in oncology clinical trials and precision medicine?
Sector sources described AI as being explored across drug development, clinical trial design, patient recruitment, results assessment, and patient selection. The sources also discussed using molecular and clinical data to identify patient groups that could benefit from more targeted cancer trials and therapies.

Why are patient selection and biomarkers important in cancer drug development?
The sector sources discussed increasingly precise molecular subtyping and biomarker-defined patient groups as oncology development became more personalized. Rakovina and Celvion said their collaboration would seek clinically actionable hypotheses to guide combination studies, biomarker-driven patient selection, and subsequent clinical development programs.

What are Rakovina Therapeutics' stock symbols?
Rakovina Therapeutics trades under RKV on the TSX Venture Exchange, 7JO0 on the Frankfurt Stock Exchange, and RKVTF on the OTC Markets.